Global Blood-Based Biomarker Market Size is valued at USD 7.9 Bn in 2024 and is predicted to reach USD 15.9 Bn by the year 2034 at a 7.4% CAGR during the forecast period for 2025-2034.
A blood-based biomarker refers to a measurable and quantifiable characteristic in the blood that indicates a particular physiological or pathological process, or a response to a therapeutic intervention. Biomarkers are valuable tools in medicine and research as they can provide information about normal biological processes, the presence of disease, or the response to treatment.
Blood-based biomarkers can assist in quantifying health and disease by measuring an individual's biochemistry from a simple patient blood sample. Several factors influence the blood-based biomarker market, contributing to its growth and development. These drives are frequently related to technological developments, a better understanding of disease causes, and a demand for personalized and non-invasive diagnostic methods.
However, the COVID-19 pandemic has had a substantial influence on various industries, including the healthcare industry and diagnostic markets, and has had an impact on the blood-based biomarker business. The epidemic shifted research emphasis to better understanding and managing COVID-19. Resources and efforts that were previously devoted to other diseases and biomarker research may have been redirected, potentially affecting timetables for the creation of specific blood-based biomarkers.
The Blood-Based Biomarker Market is segmented based on type, disease, and application. Based on type, the market is segmented as Screening Biomarkers, Diagnosis Biomarkers, and Others. The disease segment includes Cancer, Neurological Disorders, and Others. The application segment is segmented into Diagnostics, Drug Discovery, and Personalized Medicine.
The Diagnosis Biomarker category is expected to hold a major share in the global Blood-Based Biomarker Market in 2022. Various factors that contribute to the development, use, and progress of biomarker-based diagnostic technologies drive the blood-based biomarker-based diagnosis market. These factors represent the increasing significance of blood-based biomarkers in personalized medicine, disease identification, and therapy monitoring. Technological advances in genomes, proteomics, and metabolomics enable identifying and validating new blood-based biomarkers. High-throughput sequencing, mass spectrometry, and other omics techniques aid in discovering disease-specific biomarkers.
The Cancer segment is projected to grow rapidly in the global Blood-Based Biomarker Market. Various factors contribute to the development, use, and progress of biomarker technologies for cancer diagnosis, prognosis, and therapy monitoring, which drive the blood-based biomarker for the cancer market. Ongoing advances in genomes, proteomics, and other omics technologies help identify new blood-based cancer biomarkers. High-throughput sequencing, mass spectrometry, and other modern approaches aid in discovering and confirming biomarkers.
The North American Blood Biomarker Market is expected to register the maximum market share in revenue in the near future. The expanding usage of such markers in personalized medicine and various commercial expansion tactics employed by market players, such as partnerships and collaborations with existing pharmaceutical and biotechnological businesses in this region, can be credited to the region's substantial share. The Asia Pacific region is witnessing an increase in the prevalence of cancer, which is linked to several reasons, such as ageing populations, altered lifestyles, and exposure to environmental variables. This raises the need for blood-based biomarkers to detect and track cancer.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 7.9 Bn |
|
Revenue Forecast In 2034 |
USD 15.9 Bn |
|
Growth Rate CAGR |
CAGR of 7.4% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type, Disease, Application |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Diadem srl, Proteomedix, Cleveland Diagnostics, F. Hoffmann-La Roche Ltd., GENFIT, Nutech Cancer Biomarkers India Pvt Ltd., SysmOex Corporation, Minomic, Creative Diagnostics, Eisai Co., Ltd., C2N Diagnostics and Others |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Blood Based Biomarker Market Snapshot
Chapter 4. Global Blood Based Biomarker Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Type Estimates & Trend Analysis
5.1. By Type, & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Type:
5.2.1. Screening Biomarker
5.2.2. Diagnosis Biomarker
5.2.3. Others
Chapter 6. Market Segmentation 2: By Disease Estimates & Trend Analysis
6.1. By Disease & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Disease:
6.2.1. Cancer
6.2.2. Neurological Disorders
6.2.3. Others
Chapter 7. Market Segmentation 3: By Application Estimates & Trend Analysis
7.1. By Application & Market Share, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Application:
7.2.1. Diagnostics
7.2.2. Drug Discovery
7.2.3. Personalized Medicine
Chapter 8. Blood Based Biomarker Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Blood Based Biomarker Market revenue (US$ Million) estimates and forecasts By Type, 2021-2034
8.1.2. North America Blood Based Biomarker Market revenue (US$ Million) estimates and forecasts By Disease, 2021-2034
8.1.3. North America Blood Based Biomarker Market revenue (US$ Million) estimates and forecasts By Application, 2021-2034
8.1.4. North America Blood Based Biomarker Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
8.2. Europe
8.2.1. Europe Blood Based Biomarker Market revenue (US$ Million) By Type, 2021-2034
8.2.2. Europe Blood Based Biomarker Market revenue (US$ Million) By Disease, 2021-2034
8.2.3. Europe Blood Based Biomarker Market revenue (US$ Million) By Application, 2021-2034
8.2.4. Europe Blood Based Biomarker Market revenue (US$ Million) by country, 2021-2034
8.3. Asia Pacific
8.3.1. Asia Pacific Blood Based Biomarker Market revenue (US$ Million) By Type, 2021-2034
8.3.2. Asia Pacific Blood Based Biomarker Market revenue (US$ Million) By Disease, 2021-2034
8.3.3. Asia Pacific Blood Based Biomarker Market revenue (US$ Million) By Application, 2021-2034
8.3.4. Asia Pacific Blood Based Biomarker Market revenue (US$ Million) by country, 2021-2034
8.4. Latin America
8.4.1. Latin America Blood Based Biomarker Market revenue (US$ Million) By Type, (US$ Million) 2021-2034
8.4.2. Latin America Blood Based Biomarker Market revenue (US$ Million) By Disease, (US$ Million) 2021-2034
8.4.3. Latin America Blood Based Biomarker Market revenue (US$ Million) By Application, (US$ Million) 2021-2034
8.4.4. Latin America Blood Based Biomarker Market revenue (US$ Million) by country, 2021-2034
8.5. Middle East & Africa
8.5.1. Middle East & Africa Blood Based Biomarker Market revenue (US$ Million) By Type, (US$ Million) 2021-2034
8.5.2. Middle East & Africa Blood Based Biomarker Market revenue (US$ Million) By Disease, (US$ Million) 2021-2034
8.5.3. Middle East & Africa Blood Based Biomarker Market revenue (US$ Million) By Application, (US$ Million) 2021-2034
8.5.4. Middle East & Africa Blood Based Biomarker Market revenue (US$ Million) by country, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Diadem srl.
9.2.2. Proteomedix
9.2.3. Cleveland Diagnostics
9.2.4. F. Hoffmann-La Roche Ltd
9.2.5. GENFIT
9.2.6. Nutech Cancer Biomarkers India Pvt Ltd.
Blood-Based Biomarker Market By Type-
Blood-Based Biomarker Market By Disease-
Blood-Based Biomarker Market By Application-
Blood-Based Biomarker Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
